SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jensen PB, Holm B, Sorensen M, Christensen IJ, Sehested M. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to Taxotere, Taxol, topotecan and gemcitabine. Br J Cancer. 1997; 75: 869877.
  • 2
    Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol. 2001; 48: 188196.
  • 3
    Whitacre CM, Zborowska E, Gordon NH, Mackay W, Berger NA. Topotecan increases topoisomerase II alpha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res. 1997; 57: 14251428.
  • 4
    Madden T, Newman RA, Antoun G, Johansen MJ, Ali-Osman F. Low-level taxane exposure increases the activity of topoisomerase I targeted agents [abstract]. Proc Am Assoc Cancer Res. 1998; 39: 527.
  • 5
    Masumoto N, Nakano S, Esaki T, et al. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res. 1995; 15: 405409.
  • 6
    Sorensen M, Sehested M, Jensen PB. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer. 1995; 72: 399404.
  • 7
    Cheng MF, Chatterjee S, Berger NA. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncol Res. 1994; 6: 269279.
  • 8
    Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 1991; 51: 11291136.
  • 9
    Bissery MC, Vrignaud P, Lavelle F, Chabot GG. Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice. Anticancer Drugs. 1996; 7: 437460.
  • 10
    Matsuoka H, Yano K, Takiguchi S, Wakasugi H, Tomoda H. Cytotoxicity of CPT-11 against a Taxol-resistant cell line. Anticancer Res. 1997; 17: 467471.
  • 11
    Gore M, ten Bokkel Huinink W, Carmichael J, et al. Clinical evidence for topotecan-paclitaxel non-cross-resistance in ovarian cancer. J Clin Oncol. 2001; 19: 18931900.
  • 12
    Younes A, Preti HA, Hagemeister FB, et al. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol. 2001; 12: 923927.
  • 13
    Penson RT, Supko JG, Seiden MV, et al. A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent mullerian tumors. Cancer. 2001; 92: 11561167.
  • 14
    Crump M, Lipton J, Hedley D, et al. Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group study. Leukemia. 1999; 13: 343347.
  • 15
    Herben VM, ten Bokkel Huinink WW, Dubbelman AC, et al. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer. 1997; 76: 15001508.
  • 16
    O'Neill P, Clark PI, Smith D, Marshall E, Hannigan K, Ross G. A Phase I trial of a 5-day schedule of intravenous topotecan and etoposide in previously untreated patients with small-cell lung cancer. Oncology. 2001; 61 Suppl 1: 2529.
  • 17
    O'Reilly S, Fleming GF, Barker SD, et al. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol. 1997; 15: 177186.
  • 18
    Limonta M, Ubezio P, Catapano CV, et al. Doxorubicin and m-AMSA induced DNA damage in blast cells from AML patients. Leuk Res. 1991; 15: 1924.
  • 19
    Qiu J, Catapano CV, Fernandes DJ. Formation of topoisomerase II alpha complexes with nascent DNA is related to VM-26-induced cytotoxicity. Biochemistry. 1996; 35: 1635416360.
  • 20
    Danks MK, Qiu J, Catapano CV, Schmidt CA, Beck WT, Fernandes DJ. Subcellular distribution of the alpha and beta topoisomerase II-DNA complexes stabilized by VM-26. Biochem Pharmacol. 1994; 48: 17851795.
  • 21
    Danks MK, Garrett KE, Marion RC, Whipple DO. Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan. Cancer Res. 1996; 56: 16641673.
  • 22
    Wagstaff AJ, Ward A, Benfield P, Heel RC. Carboplatin. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs. 1989; 37: 162190.
  • 23
    Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem. 1997; 272: 2415924164.
  • 24
    Gupta E, Toppmeyer D, Zamek R, et al. Clinical evaluation of sequential topoisomerase targeting in the treatment of advanced malignancy. Cancer Ther. 1998; 1: 292301.
  • 25
    Ng EW, Sandler AB, Robinson L, Einhorn LH. A Phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC): a Hoosier Oncology Group study. Am J Clin Oncol. 1999; 22: 550553.
  • 26
    Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR. A randomized Phase II trial in patients with carcinoma of an unknown primary site. Cancer. 2001; 91: 592597.
  • 27
    Lilenbaum RC, Ratain MJ, Miller AA, et al. Phase I study of paclitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B study. J Clin Oncol. 1995; 13: 22302237.
  • 28
    Rosell R, Felip E, Massuti B, et al. A sequence-dependent paclitaxel/etoposide Phase II trial in patients with non-small cell lung cancer. Semin Oncol. 1997; 24 Suppl 12: S12-56S12-60.
  • 29
    Lilenbaum RC, MacManus D, Engstrom C, Green M. Phase I study of paclitaxel and etoposide for metastatic or recurrent malignancies. Am J Clin Oncol. 1998; 21: 129134.
  • 30
    Mac Manus M, Lamborn K, Khan W, Varghese A, Graef L, Knox S. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood. 1997; 89: 23032310.
  • 31
    Giovanella BC, Stehlin JS, Wall ME, et al. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science. 1989; 246: 10461048.
  • 32
    Anzai H, Frost P, Abbruzzese JL. Synergistic cytotoxicity with combined inhibition of topoisomerase (Topo) I and II [abstract]. Proc Am Assoc Cancer Res. 1992; 33: 431.
  • 33
    Chen S, Gomez SP, McCarley D, Mainwaring MG. Topotecan-induced topoisomerase IIα expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment. Cancer Chemother Pharmacol. 2002; 49: 347355.
  • 34
    Janss AJ, Cnaan A, Zhao H, et al. Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines. Anticancer Drugs. 1998; 9: 641652.
  • 35
    Bonner JA, Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol. 1996; 39: 109112.
  • 36
    Kim R, Hirabayashi N, Nishiyama M, Jinushi K, Toge T, Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancer. 1992; 50: 760766.
  • 37
    Bertrand R, O'Connor PM, Kerrigan D, Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer. 1992; 28A: 743748.
  • 38
    Johnson DH. Recent developments in chemotherapy treatment of small-cell lung cancer. Semin Oncol. 1993; 20: 315325.
  • 39
    Gerrits CJ, Burris H, Schellens JH, et al. Five days of oral topotecan (Hycamtin), a Phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer. 1998; 34: 10301035.
  • 40
    Fields SZ, Eckardt JR, Zhang L, Poulin RK, Rose G, Schiller JH. Efficacy of reduced dose of IV topotecan (T) in relapsed small cell lung cancer (SCLC) patients [abstract]. Lung Cancer. 2000; 29 Suppl 1: 10.
  • 41
    Ogawara M, Negoro S, Nishiwaki Y, Fukuoka M, Watanabe K, Niitani H. Phase II study of topotecan (TOP) for relapsed small cell lung cancer (SCLC) [abstract]. Lung Cancer. 2000; 29 Suppl 1: 40.